Prognostic value of microsatellite instability and p53 expression in metastatic colorectal cancer treated with oxaliplatin and fluoropyrimidine-based chemotherapy

Zeitschrift fur Gastroenterologie

Volumn 52, Issue 12, 2014, Pages 1394-1401

  Nopel Dunnebacke S ^a   Schulmann, K ^b   Reinacher Schick, A ^c   Porschen, R ^d   Schmiegel, W ^a   Tannapfel, A ^c   Graeven, U ^e  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b Departement of Oncology Klinikum Arnsberg   (Germany)

^c RUHR UNIVERSITY BOCHUM   (Germany)

^d Hospital Bremen East   (Germany)

^e Krankenhaus Maria Hilf   (Germany)

Author keywords

metastatic colorectal cancer; microsatellite instability; oxaliplatin; p53; prognosis

Indexed keywords

CAPECITABINE; CETUXIMAB; FLUOROPYRIMIDINE; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; PROTEIN P53; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; MICROSATELLITE DNA; PLATINUM COMPLEX; TP53 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTATIC COLORECTAL CANCER; MICROSATELLITE INSTABILITY; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; CARCINOMA; CLINICAL TRIAL; COLORECTAL NEOPLASMS; FEMALE; GENETICS; MALE; METABOLISM; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; SECONDARY; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; CARCINOMA; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; MALE; MICROSATELLITE INSTABILITY; MICROSATELLITE REPEATS; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84925311972     PISSN: 00442771     EISSN: 14397803     Source Type: Journal    
DOI: 10.1055/s-0034-1366781     Document Type: Article

References (40)

1. Tenesa A., Dunlop M. G. New insights into the aetiology of colorectal cancer from genome-wide association studies. Nat Rev Genet: 2009; 10 06 353 358
2. Issa J. Colon cancer: it's CIN or CIMP. Clin Cancer Res: 2008; 14 19 5939 5940
3. Toyota M., Ahuja N., Ohe-Toyota M. et al. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad S USA: 1999; 96 15 8681 8686
4. Ribic C. M., Sargent D. J., Moore M. J. et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med: 2003; 349 03 247 257
5. Jover R., Zapater P., Castells A. et al. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut: 2006; 55 06 848 855
6. Sargent D. J., Marsoni S., Monges G. et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol: 2010; 28 20 3219 3226
7. Sinicrope F. A., Foster N. R., Thibodeau S. N. et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst: 2011; 103 11 863 875
8. Kim S. T., Lee J., Park S. H. et al. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy. Cancer Chemother Pharmacol: 2010; 66 04 659 667
9. Flejou J. F., Andre T., Chibaudel B. et al. Effect of adding oxaliplatin to adjuvant 5-fluorouracil/leucovorin (5FU/LV) in patients with defective mismatch repair (dMMR) colon cancer stage II and III included in the MOSIAC study. J Clin Oncol: 2013; 31, suppl; abstr 3524
10. Zaanan A., Fléjou J., Emile J. et al. Defective Mismatch Repair Status as a Prognostic Biomarker of Disease-Free Survival in Stage III Colon Cancer Patients Treated with Adjuvant FOLFOX Chemotherapy. Clinical cancer research: an official journal of the American Association for Cancer Research: 2011
11. Des Guetz G., Mariani P., Cucherousset J. et al. Microsatellite instability and sensitivitiy to FOLFOX treatment in metastatic colorectal cancer. Anticancer Res: 2007; 27 04 2715 2719
12. Des Guetz G., Uzzan B., Nicolas P. et al. Microsatellite instability does not predict the efficacy of chemotherapy in metastatic colorectal cancer. A systematic review and meta-analysis. Anticancer Res: 2009; 29 05 1615 1620
13. Müller C. I., Schulmann K., Reinacher-Schick A. et al. Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group. Int J Colorectal Dis: 2008; 23 11 1033 1039
14. Braun M. S., Richman S. D., Quirke P. et al. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol: 2008; 26 16 2690 2698
15. Lane D. P. Cancer. p53, guardian of the genome. Nature: 1992; 358 6381 15 16
16. Vogelstein B. Cancer. A deadly inheritance. Nature 348 6303 681 682
17. Hollstein M., Sidransky D., Vogelstein B. et al. p53 mutations in human cancers. Science: 1991; 253 5015 49 53
18. Munro A. J., Lain S., Lane D. P. P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer: 2005; 92 03 434 444
19. Bouzourene H., Gervaz P., Cerottini J. P. et al. p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer. Eur J Cancer: 2000; 36 08 1008 1015
20. Allegra C. J., Paik S., Colangelo L. H. et al. Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol: 2003; 21 02 241 250
21. Gallego M. G., Aceñero M. J., Ortega S. et al. Prognostic influence of p53 nuclear overexpression in colorectal carcinoma. Dis Colon Rectum: 2000; 43 07 971 975
22. Propat S., Chen Z., Zhao D. et al. A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer. Ann Oncol: 2006; 17 12 1810 1817
23. Zaanan A., Cuilliere-Dartigues P., Guilloux A. et al. Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. Ann Oncol: 2010; 21 04 772 780
24. Porschen R., Arkenau H., Kubicka S. et al. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol: 2007; 25 27 4217 4223
25. Petersen S., Thames H. D., Nieder C. et al. The results of colorectal cancer treatment by p53 status: treatment-specific overview. Dis. Colon Rectum: 2001; 44 03 322 333; discussion 333-334
26. Kunstmann E., Vieland J., Brasch F. E. et al. HNPCC: six new pathogenic mutations. BMC Med Genet: 2004; 5 16
27. Engel C., Forberg J., Holinski-Feder E. et al. Novel strategy for optimal sequential application of clinical criteria, immunohistochemistry and microsatellite analysis in the diagnosis of hereditary nonpolyposis colorectal cancer. Int J Cancer: 2006; 118 01 115 122
28. Schulmann K., Brasch F. E., Kunstmann E. et al. HNPCC-associated small bowel cancer: clinical and molecular characteristics. Gastroenterology: 2005; 128 03 590 599
29. Boland C. R., Thibodeau S. N., Hamilton S. R. et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res: 1998; 58 22 5248 5257
30. Zhou X. P., Hoang J. M., Li Y. J. et al. Determination of the replication error phenotype in human tumors without the requirement for matching normal DNA by analysis of mononucleotide repeat microsatellites. Genes Chromosomes Cancer: 1998; 21 02 101 107
31. Koopman M., Kortman G. AM, Mekenkamp L. et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer: 2009; 100 02 266 273
32. Tejpar S., Bertagnolli M., Bosman F. et al. Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery. Oncologist: 2010; 15 04 390 404
33. Liang J., Huang K., Lai H. et al. High-frequency microsatellite instability predicts better chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV sporadic colorectal cancer after palliative bowel resection. Int J Cancer: 2002; 101 06 519 525
34. Brueckl W. M., Moesch C., Brabletz T. et al. Relationship between microsatellite instability, response and survival in palliative patients with colorectal cancer undergoing first-line chemotherapy. Anticancer Res 23 02 1773 1777
35. Chen W. S., Chen J. Y., Liu J. M. et al. Microsatellite instability in sporadic-colon-cancer patients with and without liver metastases. Int J Cancer: 1997; 74 04 470 474
36. Propat S., Hubner R., Houlston R. S. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol: 2005; 23 03 609 618
37. Weekes J., Ho Y., Sebesan S. et al. Irinotecan and colorectal cancer: the role of p53, VEGF-C and alpha-B-crystallin expression. Int J Colorectal Dis: 2010; 25 07 907
38. Yu J., Shannon W. D., Watson M. A. et al. Gene expression profiling of the irinotecan pathway in colorectal cancer. Clin Cancer Res: 2005; 11 05 2053 2062
39. Crea F., Giovannetti E., Cortesi F. et al. Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines. Mol. Cancer Ther: 2009; 8 07 1964 1973
40. Oden-Gangloff A., Di Fiore F., Bibeau F. et al. TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy. Br J Cancer: 2009; 100 08 1330 1335